Endogenous lipid mediators that promote inflammation resolution and tissue repair without compromising immune function.
Acute inflammation in healthy people is normally followed by a resolution phase that returns tissue to homeostasis. Dr. Charles Serhan (Harvard Medical School) and collaborators have demonstrated that inflammation resolution is a highly regulated process coordinated by Specialized Proresolving Mediators (SPMs), a superfamily of lipid autacoids that are metabolites of Omega-3 and -6 fatty acids and include the Resolvins. Resolvin E1 (RvE1) is one of the most widely investigated SPMs since its discovery 20 years ago.
In multiple models of disease, RvE1 has been shown to address key aspects of disease pathophysiology, including downregulation of inflammatory mediators and cytokines (NF-κB, TNF-α, IL-12, IL-6, IL-1β, IFN-γ), reduced neutrophil migration and infiltration, increased neutrophil apoptosis and macrophage-induced uptake of apoptotic neutrophils via efferocytosis, epithelial repair, and activation of regulatory T cells (Tregs). Taken together, these pro-resolving properties make SPMs such as RvE1 attractive, non-immunosuppressive candidates for the treatment of inflammatory disorders.
However, the development of Resolvin-based therapies has been hampered by challenges related to instability and physical-chemical properties. Using our proprietary HEALER technology, we stabilize Resolvins to enable their pharmaceutical development as patent-protected drugs. By leveraging innate biology, our approach has prospects for the safe and effective treatment of many autoimmune and inflammatory diseases.